← 返回

重编程肝胆胰肿瘤的免疫代谢:解析 TME 介导的代谢抑制并推进下一代免疫治疗策略

英文原题:Rewiring immunometabolism in hepato-biliary-pancreatic cancers: Unraveling TME-mediated metabolic suppression and advancing next-generation immunotherapeutic approaches.

查看英文原题

Rewiring immunometabolism in hepato-biliary-pancreatic cancers: Unraveling TME-mediated metabolic suppression and advancing next-generation immunotherapeutic approaches.

PubMed 2026/07/29(内容时间) Autoimmun Rev Q1 · IF 9.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝-胆-胰腺癌因其显著的异质性和不良预后而臭名昭著,在全球癌症相关死亡中持续占据主导地位。尽管免疫治疗已极大地重塑了癌症治疗格局,但由于代谢失调导致的肿瘤微环境(TME)中强烈的免疫抑制,其在这些恶性肿瘤中的疗效仍然欠佳。本综述深入分析了免疫代谢抑制的基本机制。它重点阐述了肿瘤细胞与免疫细胞竞争营养物质的策略、乳酸和腺苷等抑制性代谢产物的积累,以及破坏 CD8+ T 细胞、NK 细胞和髓系细胞中关键代谢通路,最终导致功能耗竭。本工作的新颖之处在于对这些代谢脆弱性进行了系统性分类,并引入了三管齐下的应对策略:营养物质重分配、代谢产物清除以及增强免疫细胞内在代谢。该方法旨在补充下一代免疫疗法,将免疫学上的“冷”肿瘤转化为“热”肿瘤。

此外,本综述强调了整合多组学分析、人工智能和生物标志物指导的个性化治疗作为克服耐药和增强临床疗效途径的潜力。通过从代谢视角审视治疗耐药这一挑战,本研究不仅丰富了我们对肿瘤-免疫相互作用的基础理解,还提供了一个设计高效联合疗法的实用框架,代表了在这些难治性癌症管理中的关键进展。

展开英文摘要原文

Hepato-biliary-pancreatic cancers, notorious for their pronounced heterogeneity and poor prognosis, continue to be a dominant factor in cancer-related deaths globally. Although immunotherapy has dramatically reshaped the cancer treatment landscape, its efficacy in these malignancies remains suboptimal due to the intense immunosuppression in the tumor microenvironment (TME) stemming from metabolic dysregulation. This review provides an in-depth analysis of the fundamental mechanisms of immunometabolic suppression.

It highlights the strategies employed by tumor cells to compete with immune cells for nutrients, the accumulation of inhibitory metabolitessuch as lactate and adenosine, and disrupt pivotal metabolic pathways in CD8 + T, NK, and myeloid cells, ultimately leading to functional depletion.

The novelty of this work lies in its systematic classification of these metabolic vulnerabilities and the introduction of a tripartite approach to address them: nutrient redistribution, metabolite scavenging, and enhancement of immune cell intrinsic metabolism. This approach aims to complement the next generation of immunotherapies, converting immunologically "cold" tumors into "hot" ones.

Additionally, the review emphasizes the potential of integrating multi-omics profiling, artificial intelligence, and biomarker-guided personalized therapy as avenues to overcome resistance and enhance clinical efficacy.

By viewing the challenge of therapy resistance through a metabolic perspective, this study not only enriches our foundational understanding of tumor-immune interactions but also presents a practical framework for designing highly efficacious combination therapies, representing a crucial advancement in the management of these formidable cancers.

论文信息

作者
Wu Y、Chen Z、Hu Y、Ren S、Li MY
第一作者单位
Innovation Institute of Integrated Traditional Chinese and Western Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China; Second Clinical Medical College, Guangdong Medical University, Dongguan, Guangdong, China.China
通讯作者单位
Innovation Institute of Integrated Traditional Chinese and Western Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: limy@sioc.ac.cn.China
文献类型
综述
期刊
Autoimmunity reviews2026 Jul 29
原文标识
PubMed 42526781 · DOI 10.1016/j.autrev.2026.104150